Research
MOTS-c: what the evidence shows
MOTS-c is a peptide your mitochondria already make, and the human research on it is real. Almost all of that research measures how much of it your own body releases. Studies that inject it into people and report an outcome are a different thing, and until 2026 there were none.
- The MOTS-c board ranks no provider, and carries the dated regulatory position that explains why.
- Set against another compound on the same evidence standard: MOTS-c vs Epitalon.
What MOTS-c is
MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA-c. It is a chain of sixteen amino acids encoded not in the cell nucleus but in mitochondrial DNA, which makes it one of a small family of peptides the mitochondria produce themselves.
It was discovered in 2015, which makes it young by the standards of anything sold as a therapy. What is sold under the name is a synthetic copy, and no approved MOTS-c product exists.
The biology drew attention for a good reason. A signalling molecule made by the organelle that handles cellular energy is exactly the kind of thing metabolic researchers want to understand.
The distinction that decides everything here
There are two completely different kinds of study with MOTS-c in the title, and telling them apart is the whole job.
The first kind measures how much MOTS-c is already circulating in a person's blood, usually before and after some intervention. The second kind gives a person MOTS-c and reports what happens.
The first kind is common. The second was, until recently, absent. A citation list assembled without that distinction reads as though a synthetic injection had been tested, when what was tested was a blood sample.
What the four controlled trials actually did
A PubMed search in September 2026 returns 253 records naming MOTS-c and four tagged as randomized controlled trials. Reading all four takes ten minutes and settles the question.
One studied acute endurance exercise and reported that it stimulates circulating levels of mitochondrial-derived peptides in humans. One studied aerobic and resistance exercise in breast cancer survivors and measured the effect on MOTS-c. One measured circulating MOTS-c in patients treated with metformin. One measured MOTS-c and another mitokine in men under repeated heat stress during calf immobilization.
In all four, MOTS-c is the thing being measured. In none of them is MOTS-c the thing being given. The controls confirm the search itself is sound: through the identical filter in the same session, aspirin returns 5,085 randomized controlled trials and a nonsense term returns zero.
What that evidence does and does not license
It establishes something real. MOTS-c exists in human blood, it can be measured reliably, and it responds to exercise and to at least one drug. That is genuine human pharmacology and it is why the grade here is limited rather than the bottom tier.
It does not establish that injecting a synthetic copy reproduces any of it. A molecule rising in response to exercise does not mean supplying the molecule produces the benefits of exercise. That inference is the load-bearing assumption of every MOTS-c sales page and it has not been tested.
FDA put the same point in flatter language. Its reviewers stated that assessments of dose-response relationships are missing, that the molecular targets through which MOTS-c acts remain unknown, and that it is difficult to predict which organs might be affected.
The uses regulators examined
The nomination that brought MOTS-c to the FDA Pharmacy Compounding Advisory Committee in July 2026 proposed six uses: insulin resistance, obesity, osteoporosis, vascular calcification, muscle and fat metabolism, and longevity. The agenda narrowed that to the two the agency actually evaluated, obesity and osteoporosis. The proposed product was a 5 milligram or 10 milligram subcutaneous injection.
What it is actually sold for is broader and vaguer still. FDA's own survey of the market listed regulating mitochondrial energy, promoting fat metabolism in the liver, and promoting metabolic homeostasis. It also listed improving glucose regulation, resisting metabolic stress, protecting against insulin resistance, promoting weight loss and improving physical performance.
The agency proposed not adding either form of MOTS-c to the compounding list. Its reasons were the lack of physicochemical characterization, unknown use in compounding, no nonclinical data adequate to inform safety, and no clinical studies of safety or effectiveness in humans.
Its separate safety page states the position in one sentence: FDA has not identified any human exposure data on drug products containing MOTS-c administered by any route.
The first trial that gives it to people
A registry census in September 2026 returns five studies naming MOTS-c on ClinicalTrials.gov. Four of them measure it as a biomarker inside studies of anaesthesia, diabetes, hearing or cardiovascular drugs.
One does not. A phase 2 study of MOTS-c for improving insulin sensitivity in adults with prediabetes and overweight or obesity began recruiting in early 2026, with 120 participants planned. It has posted no results.
That single study is the difference between a compound with no interventional human research and a compound with one trial underway. It is also, on its own, not an answer to anything yet.
Storage, purity and what a vial is
The reviewers found no certificate of analysis for the free base form in the nomination package. The certificate they did find for the salt form covered purity, without impurity limits, aggregates, microbial burden or endotoxin.
That gap has a practical consequence rather than a bureaucratic one. Peptides given by injection can provoke an immune response, and aggregation and peptide-related impurities raise that risk. Without impurity data there is no way to judge it in either direction.
MOTS-c is also a prohibited substance for tested athletes, listed under hormone and metabolic modulators on the World Anti-Doping Agency list that the Global Drug Reference Online database draws from.
Key takeaways
- MOTS-c is a sixteen-amino-acid peptide encoded in mitochondrial DNA and discovered in 2015.
- All four randomized controlled trials naming it measure endogenous blood levels; none administers it.
- One phase 2 study that does administer it began recruiting in early 2026 and has posted no results.
- FDA evaluated it for obesity and osteoporosis and proposed not adding it to the compounding list.
- FDA states it has identified no human exposure data for MOTS-c drug products by any route.
- The grade is limited because the biology is measured in people, not because the injectable has been tested.
Frequently asked questions
Is there human research on MOTS-c?
Yes, and most of it is not what people assume. Four randomized controlled trials name MOTS-c as of September 2026, and all four measure how much of it a person's own body is releasing during exercise, heat stress or metformin treatment. None gives MOTS-c to anyone. A single phase 2 study that does administer it began recruiting in early 2026 and has posted no results.
Why is MOTS-c graded limited rather than the bottom tier?
Because the underlying biology has been measured in people. MOTS-c is a real endogenous peptide, its blood levels can be quantified, and they respond to exercise. That is more than can be said for compounds where the entire literature is in rodents or cells. What is missing is the step that would matter to a buyer: giving the synthetic version to a person and reporting a health outcome.
Does injecting MOTS-c mimic exercise?
No study has tested that. The observation behind the claim is that exercise raises circulating MOTS-c. Reversing the arrow, so that supplying MOTS-c produces the effects of exercise, is an assumption rather than a finding. FDA noted that the molecular targets through which MOTS-c acts are unknown, which makes the mechanism for such an effect unspecified as well.
What did FDA conclude about MOTS-c?
It proposed not adding either the free base or the acetate to the list of substances that may be used in compounding under section 503A. The stated grounds were four. The substances are not well characterized chemically. The extent of use in compounding is unknown. No nonclinical data adequate to inform safety exists, and no clinical studies of safety or effectiveness in humans have been published. It evaluated the compound for obesity and osteoporosis.
Is MOTS-c banned in sport?
It is listed as a prohibited substance under hormone and metabolic modulators, according to the Global Drug Reference Online database that draws on the World Anti-Doping Agency prohibited list. Anyone subject to testing should treat that as decisive regardless of what they conclude about the evidence.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- FDA Briefing Document for MOTS-c-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee — U.S. Food and Drug Administration, May 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — U.S. Food and Drug Administration, April 2026
- Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans — Journal of Applied Physiology, September 2021
- Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors — Scientific Reports, August 2021
- Repeated heat stress modulates the levels of the mitokines MOTS-c and FGF21 in active men during calf muscle immobilization — Medicine and Science in Sports and Exercise, December 2025
- Registered study census for MOTS-c, run with a positive control through the same query — ClinicalTrials.gov, National Library of Medicine, September 2026